Skip to main content
. Author manuscript; available in PMC: 2012 May 13.
Published in final edited form as: Cancer Lett. 2009 Feb 23;278(2):201–209. doi: 10.1016/j.canlet.2009.01.009

Fig. 5.

Fig. 5

The expression of Bcl-2, Bcl-xL, caspase-3, survivin, and β-actin in ME-180PT, and UMSCC-5 SCC cell line treated with 1 μM cisplatin, 25 μM B-DIM, 25 μM G2535, or the combination of B-DIM and cisplatin (Cis) or G2535 and Cis for 72 h. Significant down-regulation of all the proteins was observed in cells treated with both the combinations compared to cells treated with either agent alone.